Article Information
History
- October 13, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Isabella A.T.M. Ferreira1,2,**,
- Colin Y.C. Lee3,4,**,
- William Foster5,**,
- Adam Abdullahi1,2,
- Zewen Kelvin Tuong3,4,
- Benjamin J Stewart3,4,
- John R. Ferdinand3,
- Stephane Guillaume5,
- Martin O.P. Potts1,2,
- Marianne Perera1,2,
- Benjamin A. Krishna1,2,
- Ana P. Alonso3,
- Mia Cabantous3,
- Steven A. Kemp1,2,
- Lourdes Ceron-Gutierrez6,
- Soraya Ebrahimi6,
- The CITIID-NIHR BioResource COVID-19 Collaboration,
- Paul Lyons1,2,
- Kenneth GC Smith1,2,
- John Bradley1,2,
- Dami A. Collier1,2,
- Sarah A. Teichmann4,
- Laura E. McCoy7,
- Paul A. MacAry8,
- Rainer Doffinger6,
- Mark R. Wills1,2,
- Michelle Linterman5,*,
- Menna R. Clatworthy1,3,4,* and
- Ravindra K. Gupta1,2,*
- 1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
- 2Department of Medicine, University of Cambridge, Cambridge, UK
- 3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
- 4Wellcome Sanger Institute, Cambridge, UK
- 5Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK
- 6Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK
- 7Division of infection and immunity, UCL, London, UK
- 8National University of Singapore, Singapore
- ↵*Correspondence to: Michelle Linterman Michelle.Linterman{at}babraham.ac.uk, Menna R. Clatworthy mrc{at}cam.ac.uk, Ravindra K. Gupta rkg20{at}cam.ac.uk
↵** equal contribution